Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy

Hepatology. 2019 Oct;70(4):1437-1442. doi: 10.1002/hep.30633. Epub 2019 Sep 19.

Abstract

Although patients undergo procedures with curative intent for early-stage hepatocellular carcinoma (HCC), up to 70% of patients may have disease recurrence in the liver at 5 years. Thus far, no therapy has proven to be effective in the adjuvant setting. Here, we discuss the application of immune-based therapies in the adjuvant setting for HCC, focusing on the underlying rationale for immunotherapies, which patients may benefit from an immune-based therapy, and what type of immune therapy should be implemented.

Publication types

  • Research Support, N.I.H., Intramural
  • Review

MeSH terms

  • Carcinoma, Hepatocellular / diagnosis
  • Carcinoma, Hepatocellular / mortality
  • Carcinoma, Hepatocellular / therapy*
  • Chemotherapy, Adjuvant
  • Disease-Free Survival
  • Female
  • Forecasting
  • Hepatectomy / methods
  • Humans
  • Immunotherapy / methods*
  • Liver Neoplasms / diagnosis
  • Liver Neoplasms / mortality*
  • Liver Neoplasms / therapy*
  • Male
  • Neoplasm Recurrence, Local / mortality
  • Neoplasm Recurrence, Local / parasitology
  • Neoplasm Recurrence, Local / therapy*
  • Risk Assessment
  • Survival Analysis
  • Treatment Outcome